Trial Profile
Trastuzumab in HER2-negative Early Breast Cancer as Adjuvant Treatment for Circulating Tumor Cells
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms TREAT CTC
- 22 Jul 2020 This trial has been completed in UK (Global End Date: 22 Aug 2018), according to European Clinical Trials Database record.
- 15 Mar 2019 This trial has been completed in Belgium, according to European Clinical Trials Database.
- 11 Jun 2018 Primary endpoint (CTC detection )has not been met, according to the results published in the Annals of Oncology